Patents Assigned to Daiichi Sankyo Company, Limited
  • Anti-garp antibody
    Patent number: 10550198
    Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: February 4, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kazuki Satoh, Kazuki Hirahara, Ichiro Watanabe, Masato Amano
  • Peptide library and use thereof
    Patent number: 10550154
    Abstract: Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: February 4, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Ryuji Hashimoto
  • THERAPEUTIC AGENT FOR SHORT STATURE
    Publication number: 20200030414
    Abstract: The present invention provides a therapeutic agent for failure-to-thrive or short stature which contains C-type natriuretic peptide (CNP) or a CNP derivative as an active ingredient, reduces adverse reactions, and exhibits excellent efficacy, and a method for treating failure-to-thrive or short stature.
    Type: Application
    Filed: January 23, 2018
    Publication date: January 30, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Naomi Morozumi, Mayumi Furuya, Toshimasa Jindo, Yasuyuki Abe, Shiuhei Mieda, Akiko Ohno
  • ANTI-GPR20 ANTIBODY
    Publication number: 20200017583
    Abstract: It is an object of the present invention to provide an anti-GPR20 antibody that can be used in the detection of GPR20, a reagent for GPR20 detection comprising the antibody, a reagent for diagnosis or a composition for testing of a disease related to the expression of GPR20, etc. The present invention provides an antibody specifically binding to a peptide comprising the amino acid sequence at amino acid positions 1 to 48 in SEQ ID NO: 1, or an antigen-binding fragment of the antibody, a chimeric antibody of the antibody, a rabbit type antibody of the antibody, etc. The present invention also provides a composition comprising the antibody, etc.
    Type: Application
    Filed: March 29, 2018
    Publication date: January 16, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kenji IIDA, Tomoko SHIBUTANI, Kensuke NAKAMURA, Masato AMANO
  • UREA DERIVATIVE
    Publication number: 20200017439
    Abstract: An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect, and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound represented by the following formula, or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and represent a C1-C6 alkyl group or the like, and Ar represents an optionally substituted phenyl group or an optionally substituted thienyl group.
    Type: Application
    Filed: October 5, 2017
    Publication date: January 16, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tsuyoshi Soneda, Yuji Nakamura, Koji Matsumoto, Naomi Tanaka, Taichi Fukunaga
  • Cationic lipid
    Patent number: 10533176
    Abstract: The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: January 14, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Makoto Koizumi, Yoshiyuki Onishi, Takako Niwa, Masakazu Tamura, Yuji Kasuya
  • ANTI-ALK2 ANTIBODY
    Publication number: 20200002427
    Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
    Type: Application
    Filed: August 19, 2019
    Publication date: January 2, 2020
    Applicants: SAITAMA MEDICAL UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: TAKENOBU KATAGIRI, KENJI OSAWA, SHO TSUKAMOTO, SHINNOSUKE TSUJI, YOSHIROU KAWAGUCHI, KENSUKE NAKAMURA
  • GRISEOFULVIN COMPOUND
    Publication number: 20200002302
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Application
    Filed: September 5, 2019
    Publication date: January 2, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Combination of TAFIa inhibitor with plasminogen activator
    Patent number: 10517850
    Abstract: The present invention provides a pharmaceutical composition for treatment or prevention of thrombosis or embolism or a sequela thereof, comprising a particular TAFIa inhibitor and a plasminogen activator, the TAFIa inhibitor being administered in combination with the plasminogen activator, and a method for treating or preventing thrombosis or embolism or a sequela thereof, comprising administering a particular TAFIa inhibitor in combination with a plasminogen activator to a warm-blooded animal.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: December 31, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kengo Noguchi, Yusuke Ito, Naoko Edo
  • METHOD FOR PREDICTING SENSITIVITY OF CANCER TO TREATMENT WITH PD-1 IMMUNE CHECKPOINT INHIBITOR
    Publication number: 20190376146
    Abstract: The present invention provides a gene set for predicting the sensitivity of a cancer to a treatment with a PD-1 immune checkpoint inhibitor. More specifically, the present invention provides one or more genes selected from the group consisting of ADAM8, VCL, LEF1-AS1, TSPAN32, CTBP2, RXRA, PTGDS, ITGB1, KLRD1, RAB11FIP5, SLC4A8, NIN, GCNT2, ASB2, HNRPLL, AMPD3, SIRPG, PTPN13, MYB, ASAP1, MBOAT1, COTL1, ICOS, ST8SIA1, PASK, SGPP2, PDCD1, TBC1D4, EMP3, FAM65B, GBP1, FAM211B, PRR5, C17orf67, FAM101B and TBL1X, and a method for predicting the sensitivity of a cancer to a treatment with a PD-1 immune checkpoint inhibitor by using the genes.
    Type: Application
    Filed: November 22, 2017
    Publication date: December 12, 2019
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shinnosuke YAMADA, Naoki KIYOSAWA
  • AMIDE DERIVATIVE
    Publication number: 20190365688
    Abstract: An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect, and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. Provided is a pharmaceutical composition containing, as an active ingredient, a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula (I), R1 and R2 are the same or different, and represent a C1-C6 alkyl group, a halogeno C1-C6 alkyl group or a C3-C6 cycloalkyl group; n represents 0, 1 or 2; each X represents a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a halogen atom or the like; and Y represents a hydrogen atom, a C1-C6 alkoxy group, a C3-C6 cycloalkoxy group or a halogeno C1-C6 alkoxy group.
    Type: Application
    Filed: February 20, 2018
    Publication date: December 5, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tsuyoshi Soneda, Hiroki Sakai, Koji Matsumoto, Naomi Tanaka, Taichi Fukunaga
  • ANTI-GPRC5D ANTIBODY AND MOLECULE CONTAINING SAME
    Publication number: 20190367612
    Abstract: The present disclosure provides a novel antibody that binds to human GPRC5D; a molecule with human GPRC5D binding activity, which comprises the antibody; and an anti-tumor pharmaceutical composition comprising the antibody or the molecule as an active.
    Type: Application
    Filed: June 2, 2018
    Publication date: December 5, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Takashi CHAEN, Toshiaki OHTSUKA, Kenji IIDA, Kensuke NAKAMURA, Takahide ABURATANI, Junya ICHIKAWA, Shota KUDO, Chayne Lee PISCITELLI, Mario SANCHES
  • ANTI-CD3 ANTIBODY AND MOLECULES COMPRISING THE ANTIBODY
    Publication number: 20190359712
    Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.
    Type: Application
    Filed: December 21, 2017
    Publication date: November 28, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tohru TAKAHASHi, Chigusa YOSHIMURA, Shiho KOZUMA, Kensuke NAKAMURA, Chikako SUZUKI, Junya ICHIKAWA
  • Treatment method by combined use of MDM2 inhibitor and BTK inhibitor
    Patent number: 10485794
    Abstract: It is intended to provide a medicament and a method for treating cancer comprising a compound having MDM2 inhibiting activity and a compound having BTK inhibiting activity in combination. The present invention provides a medicament comprising (3?R,4?S,5?R)—N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6?-chloro-4?-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2?-oxo-1?,2?-dihydrodispiro[cyclohexane-1,2?-pyrrolidine-3?,3?-indole]-5?-carboxamide or a pharmaceutically acceptable salt thereof and ibrutinib or a pharmaceutically acceptable salt thereof in combination, and a treatment method using these compounds or salts in combination.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: November 26, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Takahiko Seki
  • Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof
    Patent number: 10478496
    Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: November 19, 2019
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Chigusa Yoshimura, Reimi Kawaida, Kokichi Honda
  • PHARMACEUTICAL COMPOSITION USED FOR TREATMENT OF HTLV-1-ASSOCIATED MYELOPATHY
    Publication number: 20190343816
    Abstract: The present invention provides a pharmaceutical composition containing an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor as an active ingredient, for use in treating HTLV-1-associated myelopathy. The present invention provides a pharmaceutical composition for use in treating HTLV-1-associated myelopathy, containing a 1,3-benzodioxole derivative or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 18, 2018
    Publication date: November 14, 2019
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Yoshihisa YAMANO, Natsumi UEDA, Kazushi ARAKI
  • DNA ELEMENT HAVING THE ACTIVITY OF ENHANCING FOREIGN GENE EXPRESSION
    Publication number: 20190345515
    Abstract: A method for stably achieving high expression of a foreign gene in mammalian cells using a novel DNA element is disclosed. More specifically, the present application discloses a DNA element which enhances the activation of transcription by changing the chromatin structure around a gene locus into which a foreign gene expression unit has been introduced.
    Type: Application
    Filed: July 26, 2019
    Publication date: November 14, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Tatsuya Inoue
  • THERAPY FOR DRUG-RESISTANT CANCER BY ADMINISTRATION OF ANTI-HER2 ANTIBODY/DRUG CONJUGATE
    Publication number: 20190330368
    Abstract: As treatment effective for HER2-expressing cancer having resistance or refractoriness to an existing anti-HER2 drug, there are provided a therapeutic agent and a treatment method using an antibody-drug conjugate in which a linker and a drug represented by the formula: -(Succinimid-3-yl-N)—CH2CH2CH2CH2CH2—C(?O)-GGFG-NH—CH2—O—CH2—C(?O)—(NH-DX) are conjugated to an anti-HER2 antibody.
    Type: Application
    Filed: October 5, 2017
    Publication date: October 31, 2019
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takahiro JIKOH, Yusuke OGITANI, Kazutaka YOSHIHARA, Seiko ENDO, Yoshihiko FUJISAKI
  • Anti-Orai1 Antibody
    Publication number: 20190322740
    Abstract: It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T cell activation.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 24, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tomoaki Komai, Takako Kimura, Daichi Baba, Yoshikuni Onodera, Kento Tanaka, Takashi Kagari, Anri Aki, Nobumi Nagaoka
  • Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
    Patent number: RE47672
    Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are, the isolation and identification of polynucleotides, polypeptides, variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: October 29, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Roy Rabindranauth Sooknanan, Gilles Bernard Tremblay, Mario Filion